Pharmacotherapy for community-acquired pneumonia in the elderly

References

• Simonetti AF, Viasus D, Garcia-Vidal C, et al. Management of community-acquired pneumonia in older adults. Ther Adv Infect Dis. 2014;2:3–16.
   PubMedGoogle Scholar
• May DS, Kelly JJ, Mendlein JM, et al. Surveillance of major causes of hospitalization among the elderly, 1988. MMWR CDC Surveill Summ. 1991;40:7–21.
   PubMedGoogle Scholar
• Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–837.
   PubMed Web of Science ®Google Scholar
• González-Castillo J, Martín-Sánchez FJ, Llinares P, et al.; Spanish Society of Emergency Medicine and Emergency Care; Spanish Society of Geriatrics and Gerontology; Spanish Society of Chemotherapy; Spanish Society of Pneumology and Thoracic Surgery; Spanish Society of Home Hospitalization. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev Esp Quimioter. 2014;27:69–86.
   PubMed Web of Science ®Google Scholar
• Torner N, Izquierdo C, Soldevila N, et al.; Project PI12/02079 Working Group. Factors associated with 30-day mortality in elderly inpatients with community acquired pneumonia during 2 influenza seasons. Hum Vaccin Immunother. 2017;13:450–455.
   PubMed Web of Science ®Google Scholar
• Ochoa-Gondar O, Vila-Córcoles A, De Diego C, et al.; EVAN-65 Study Group. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 study. BMC Public Health. 2008;8:222.
   PubMed Web of Science ®Google Scholar
• Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med. 2002;165:766–772.
   PubMed Web of Science ®Google Scholar
• Jain S, Self WH, Wunderink RG, et al.; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–427.
   PubMed Web of Science ®Google Scholar
• Fernández-Sabé N, Carratalà J, Rosón B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore). 2003;82:159–169.
   PubMed Web of Science ®Google Scholar
• Ho JC, Chan KN, Hu WH, et al. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am J Respir Crit Care Med. 2001;163:983–988.
   PubMed Web of Science ®Google Scholar
• Meyer KC. The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol. 2001;128:23–31.
   PubMedGoogle Scholar
• Boe DM, Boule LA, Kovacs EJ. Innate immune responses in the ageing lung. Clin Exp Immunol. 2017;187:16–25.
   PubMed Web of Science ®Google Scholar
• Murray MA, Chotirmall SH. The impact of immunosenescence on pulmonary disease. Mediators Inflamm. 2015;2015:692546.
   PubMed Web of Science ®Google Scholar
• Jackson ML, Nelson JC, Jackson LA. Risk factors for community-acquired pneumonia in immunocompetent seniors. J Am Geriatr Soc. 2009;57:882–888.
   PubMed Web of Science ®Google Scholar
• Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med. 1996;154:1450–1455.
   PubMed Web of Science ®Google Scholar
• Skull SA, Andrews RM, Byrnes GB, et al. Hospitalized community-acquired pneumonia in the elderly: an Australian case-cohort study. Epidemiol Infect. 2009;137:194–202.
   PubMed Web of Science ®Google Scholar
• Nosè M, Recla E, Trifirò G, et al. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2015;24:812–820.
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al.; EPIVAC Study Group. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309–316.
   PubMed Web of Science ®Google Scholar
• Kolditz M, Ewig S, Klapdor B, et al.; CAPNETZ study group. Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax. 2015;70:551–558.
   PubMed Web of Science ®Google Scholar
• García-Ordóñez MA, García-Jiménez JM, Páez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis. 2001;20:14–19.
   PubMed Web of Science ®Google Scholar
• Pieralli F, Vannucchi V, Mancini A, et al. Delirium is a predictor of in-hospital mortality in elderly patients with community acquired pneumonia. Intern Emerg Med. 2014;9:195–200.
   PubMed Web of Science ®Google Scholar
• Calle A, Márquez MA, Arellano M, et al. Geriatric assessment and prognostic factors of mortality in very elderly patients with community-acquired pneumonia. Arch Bronconeumol. 2014;50:429–434.
   PubMed Web of Science ®Google Scholar
• Wesemann T, Nüllmann H, Pflug MA, et al. Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: a cohort study. BMC Infect Dis. 2015;15:2.
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313:264–274.
   PubMed Web of Science ®Google Scholar
• Davydow DS, Hough CL, Levine DA, et al. Functional disability, cognitive impairment, and depression after hospitalization for pneumonia. Am J Med. 2013;126:615–624.e5.
   PubMed Web of Science ®Google Scholar
• Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. Am J Respir Crit Care Med. 1997;156:1908–1914.
   PubMed Web of Science ®Google Scholar
• Faverio P, Aliberti S, Bellelli G, et al. The management of community-acquired pneumonia in the elderly. Eur J Intern Med. 2014;25:312–319.
   PubMed Web of Science ®Google Scholar
• Basi SK, Marrie TJ, Huang JQ, et al. Patients admitted to hospital with suspected pneumonia and normal chest radiographs: epidemiology, microbiology, and outcomes. Am J Med. 2004;117:305–311.
   PubMed Web of Science ®Google Scholar
• El-Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med. 2001;163(3 Pt 1):645–651.
   PubMed Web of Science ®Google Scholar
• Rello J, Rodriguez R, Jubert P, et al. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis. 1996;23(4):723–728.
   PubMed Web of Science ®Google Scholar
• Taylor JK, Fleming GB, Singanayagam A, et al. Risk factors for aspiration in community-acquired pneumonia: analysis of a hospitalized UK cohort. Am J Med. 2013;126:995–1001.
   PubMed Web of Science ®Google Scholar
• van der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM, et al. Risk factors for aspiration pneumonia in frail older people: a systematic literature review. J Am Med Dir Assoc. 2011;12:344–354.
   PubMed Web of Science ®Google Scholar
• Teramoto S, Yoshida K, Hizawa N. Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respir Investig. 2015;53:178–184.
   PubMedGoogle Scholar
• Cilloniz C, Ceccato A, San Jose A, et al. Clinical management of community acquired pneumonia in the elderly patient. Expert Rev Respir Med. 2016 Oct 3. [Epub ahead of print]. doi:10.1080/17476348.2016.1240037.
   PubMed Web of Science ®Google Scholar
• Dumke R, Schnee C, Pletz MW, et al.; Capnetz Study Group. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerg Infect Dis. 2015;21:426–434.
   PubMed Web of Science ®Google Scholar
• Cillóniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013;144:999–1007.
   PubMed Web of Science ®Google Scholar
• Petrosillo N, Cataldo MA, Pea F. Treatment options for community-acquired pneumonia in the elderly people. Expert Rev Anti Infect Ther. 2015;13:473–485.
   PubMed Web of Science ®Google Scholar
• Von Baum H, Welte T, Marre R, et al.; CAPNETZ study group. Community-acquired pneumonia through enterobacteriaceae and pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur Respir J. 2010;35:598–605.
   PubMed Web of Science ®Google Scholar
• Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother. 2014;58:5262–5268.
   PubMed Web of Science ®Google Scholar
• Ewig S, Klapdor B, Pletz MW, et al. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax. 2012;67:132–138.
   PubMed Web of Science ®Google Scholar
• McLachlan A, Pont L. Drug metabolism in older people – a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci. 2012;67A:175–180.
   Web of Science ®Google Scholar
• Mangoni A, Jackson S. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6–14.
   Web of Science ®Google Scholar
• Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331–339.
   PubMed Web of Science ®Google Scholar
• Midlov P. Pharmacokinetics and pharmacodynamics in the elderly. OA Elder Med. 2013;1:1.
   Google Scholar
• Aymanns C, Keller F, Maus S, et al. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol. 2010;5:314–327.
   PubMed Web of Science ®Google Scholar
• Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am. 2004;18:451–456.
   PubMed Web of Science ®Google Scholar
• Bradley S. Principles of antimicrobial therapy in older adults. Clin Geriatr Med. 2016;32:443–457.
   PubMed Web of Science ®Google Scholar
• McKinnon PS, Davis SL. Pharmacokinetic and pharmacodynamics issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis. 2004;23:277.
   Web of Science ®Google Scholar
• Simonetti AF, van Werkhoven CH, Schweitzer VA, et al. Predictors for individual patient antibiotic treatment effect in hospitalised community-acquired pneumonia patients. Clin Microbiol Infect. 2017 Mar 20. [Epub ahead of print]. DOI:10.1016/j.cmi.2017.03.010.
   Google Scholar
• Avni T, Shiver-Ofer S, Leibovici L, et al. Participation of elderly adults in randomized controlled trials addressing antibiotic treatment of pneumonia. J Am Geriatr Soc. 2015;63:233–243.
   PubMed Web of Science ®Google Scholar
• Majcher-Peszynska J, Loebermann M, Klammt S, et al.; CAPNETZ Study Group. Ampicillin/sulbactam in elderly patients with community-acquired pneumonia. Infection. 2014;42:79–87.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al.; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infect. 2011;17 Suppl 6:E1–59.
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27–S72.
   PubMed Web of Science ®Google Scholar
• Okimoto N, Kurihara T, Honda N, et al. Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly. J Infect Chemother. 2003;9:183–186.
   PubMedGoogle Scholar
• Cios A, Wyska E, Szymura-Oleksiak J, et al. Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections. Exp Gerontol. 2014;57:107–113.
   PubMed Web of Science ®Google Scholar
• Tilekeeva U, Janbaeva A. The use of drugs for the elderly with community-acquired pneumonia. Clin Ther. 2016;38:e27–e28.
   PubMedGoogle Scholar
• Morganroth J, Dimarco JP, Anzueto A, et al.; CAPRIE Study Group. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest. 2005;128:3398–3406.
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311:2199–2208.
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366:1881–1890.
   PubMed Web of Science ®Google Scholar
• Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med. 2013;368(18):1704–1712.
   PubMed Web of Science ®Google Scholar
• Schembri S, Williamson PA, Short PM, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235.
   PubMed Web of Science ®Google Scholar
• Sligl WI, Asadi L, Eurich DT, et al. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med. 2014;42:420–432.
   PubMed Web of Science ®Google Scholar
• Kertland H, Kays MB. Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death? Can J Hosp Pharm. 2013;66:328–331.
   PubMedGoogle Scholar
• Westphal JF. Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol. 2000;50:285–295.
   PubMed Web of Science ®Google Scholar
• Parekh TM, Raji M, Lin Y-L, et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med. 2014;174:1605–1612.
   PubMed Web of Science ®Google Scholar
• Corrao G, Zambon A, Bertù L, et al. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Drug Saf. 2006;29:889–896.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Holmes HM, Lin Y-L, et al. Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults. Am J Med. 2012;125:183–189.
   PubMed Web of Science ®Google Scholar
• Goodman LS, Gilman A, Brunton LL, et al. Goodman & Gilman’s the pharmacological basis of therapeutics. New York (NY): McGraw-Hill; 2006.
   Google Scholar
• Arnold FW, LaJoie AS, Brock GN, et al.; Community-Acquired Pneumonia Organization (CAPO) Investigators. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med. 2009;169:1515–1524.
   PubMedGoogle Scholar
• Egger ME, Myers JA, Arnold FW, et al. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for community-aquired pneumonia. BMC Med Inform Decis Mak. 2016;16:34.
   PubMed Web of Science ®Google Scholar